NovoCureNVCR
NVCR
About: NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Employees: 1,488
0
Funds holding %
of 7,295 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
692% more call options, than puts
Call options by funds: $21.2M | Put options by funds: $2.68M
1.97% more ownership
Funds ownership: 84.63% [Q4 2024] → 86.6% (+1.97%) [Q1 2025]
7% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 76
5% less funds holding
Funds holding: 238 [Q4 2024] → 227 (-11) [Q1 2025]
17% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 47
38% less capital invested
Capital invested by funds: $2.73B [Q4 2024] → $1.7B (-$1.03B) [Q1 2025]
60% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 2 (-3) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$27
48%
upside
Avg. target
$30
63%
upside
High target
$34
87%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Piper Sandler Jason Bednar | 87%upside $34 | Overweight Maintained | 23 Apr 2025 |
Wedbush David Nierengarten | 48%upside $27 | Neutral Maintained | 16 Apr 2025 |
JP Morgan Jessica Fye | 54%upside $28 | Neutral Maintained | 10 Apr 2025 |
Financial journalist opinion
Based on 8 articles about NVCR published over the past 30 days
Neutral
Zacks Investment Research
6 days ago
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
Positive
Benzinga
1 week ago
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
Zai Lab Limited ZLAB and NovoCure Limited NVCR revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.
Neutral
Business Wire
1 week ago
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. “The data presented today from the PANOVA-3 trial of Tumor Treating.
Neutral
Business Wire
1 week ago
Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. “The data presented today from the PANOVA-3 trial of Tumor Treating Fields show a clinically meaningful and statistically significant improvement.
Negative
The Motley Fool
2 weeks ago
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
It's been a challenging year for NovoCure (NVCR 3.51%), an oncology-focused biotech. The stock is down by 35% since early January.
Neutral
Business Wire
2 weeks ago
Novocure Announces Upcoming Investor Events
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novocure leadership will be joined by Vincent Picozzi, MD, MMM, medical oncologist and investigator in the.
Positive
Seeking Alpha
2 weeks ago
NovoCure: Loading Up On Growth Catalysts
NovoCure's Q1 earnings beat and strong commercial momentum, especially with Optune Lua in NSCLC, signal renewed growth potential and investor optimism. Key catalysts ahead include the PANOVA-3 data at ASCO, PMA submissions, and possible NCCN guideline inclusion, all of which could drive adoption and revenue. International expansion, particularly in Europe and Japan, is accelerating, with robust demand and a solid cash position supporting pipeline and scaling efforts.
Positive
Zacks Investment Research
4 weeks ago
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
The mean of analysts' price targets for NovoCure (NVCR) points to a 105.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
The Motley Fool
1 month ago
Why NovoCure Stock Skyrocketed This Week
Shares of NovoCure (NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m.
Charts implemented using Lightweight Charts™